Related Experiment Video

Updated: Aug 14, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Strategies for designing clinical trials for oligonucleotide therapeutics

Volker Wacheck1

  • 1Department of Clinical Pharmacology, Section of Experimental Oncology and Molecular Pharmacology, Medical University Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Volker.Wacheck@meduniwien.ac.at

Drug Discovery Today
|October 27, 2004
PubMed

Insights

Clinical trial designs for oligonucleotide therapeutics need improvement. Focusing on biologically active doses and innovative trial designs can enhance the efficiency of oligonucleotide drug development.

Area of Science:

  • Pharmacology
  • Clinical Trial Design
  • Oligonucleotide Therapeutics

Background:

  • Recent Phase III trials for oligonucleotide therapeutics have shown disappointing outcomes.
  • Evidence suggests that trial designs must account for the specific mode of action of these compounds.
  • Current trial methodologies may not be optimal for evaluating oligonucleotide efficacy.

Purpose of the Study:

  • To highlight the importance of tailored trial designs for oligonucleotide therapeutics.
  • To recommend adjustments in early-phase trial endpoint selection.
  • To suggest strategies for improving late-phase clinical trial efficiency.

Main Methods:

  • Review of recent clinical trial outcomes for oligonucleotide therapeutics.
  • Analysis of the impact of trial design on therapeutic success.
  • Synthesis of evidence regarding endpoint selection and population enrichment.

Main Results:

  • Disappointing results in recent Phase III trials indicate a need for revised approaches.
  • Considering the specific mode of action is crucial for effective clinical testing.
  • Early trials should evaluate biologically active doses, not just maximal tolerated doses.

Conclusions:

  • Optimizing clinical trial designs is essential for the success of oligonucleotide therapeutics.
  • Implementing alternative endpoints and innovative designs can improve trial efficiency.
  • Future trials should incorporate biologically informed endpoints and sensitive population selection.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Using Modified Synthetic Oligonucleotides to Assay Nucleic Acid-Metabolizing Enzymes05:33

Using Modified Synthetic Oligonucleotides to Assay Nucleic Acid-Metabolizing Enzymes

Published on: July 5, 2024

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...